FDA Outlines Rules on Genetically Engineered Animals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
FDA Outlines Rules on Genetically Engineered Animals


ePT--the Electronic Newsletter of Pharmaceutical Technology

Rockville, MD (Sept. 24)—In an effort to clarify its policy on the use and creation of genetically engineered (GE) animals, the US Food and Drug Administration released the draft guidance The Regulation of Genetically Engineered Animals Containing Heritable rDNA Constructs on Sept. 18, 2008. The guidance also outlines requirements and recommendations already existing in regards to GE animals and products derived from GE animals.

GE animals are animals whose DNA has been manipulated with a recombinant DNA (rDNA) construct to bring about new or specific traits. These animals are used to create pharmaceuticals, serve as models for human diseases, and produce consumer products.  According to FDA, rDNA constructs meet the definition of a new animal drug under the Food, Drug, and Cosmetic Act (FD&C Act), which classifies “articles (other than food) intended to affect the structure or any function of the body of man or other animals” as drugs. 

“Genetically engineered animals hold great promise for improving human medicine, agriculture, the environment, and the production of new materials, and FDA has long been involved in the scientific evaluation. Our guidance provides a framework for both GE animals and products made from them to reach the market,” stated deputy commission for policy Randall Lutter, PhD, in a press release.

The guidance indicates areas in which FDA will be coordinating with other federal agencies in the US Department of Agriculture and the Environment Protection Agency to develop policies in regard to GE animals. Specific questions addressed in the guidance include FDA’s enforcement entitlements, current regulations, and product development processes. The guidance also outlines the responsibilities for meeting environmental assessment under the National Environmental Policy Act for those applying for an animal drug application.  The draft guidance is limited to heritable rDNA constructs. Nonheritable constructs may be addressed in a future guidance.

Public comment on the draft guidance is open until November 18, 2008. A copy of the guidance can be downloaded here.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
In light of the fact that most of the world is now out of the recession, how is your company faring compared with this time last year?
Better
Worse
About the same
Better
54%
Worse
25%
About the same
21%
View Results
Jim MillerOutsourcing OutlookJim Miller Time for a Model Upgrade
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Navigating the Global Pharmaceutical Supply Chain
Faiz kermaniSpotlightFaiz Kermani Reinvigorating European R&D innovation
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Shelves Await Pediatric Formulations
FDA, Pharma, and Alliance Partner to Treat TB
Framing the argument
Pharma Companies and Suppliers Meet at DCAT Week
Biopharmaceutical Collaboration Is a Sign of the Times
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here